Xilio Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Xilio Therapeutics, Inc. | XLO - NASDAQ |
$16.00-$18.00 | $16.00 | $15.00 | 7.35 million | 10/22/2021 |
| Morgan Stanley, Cowen, Guggenheim Securities | ||||||
Co-Manager(s): Raymond James | ||||||
| Health Care | ||||||
Filing(s): Terms Added 2021-10-18 | ||||||
Xilio Therapeutics, Inc. Quote & Chart - Click for current quote - XLO
IPO Boutique aggregates information on public companies and private companies, such as "XLO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Xilio Therapeutics, Inc. (adapted from Xilio Therapeutics, Inc. prospectus):
They are a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "XLO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.